慢性丁型肝炎与肝细胞癌:观察性研究的系统综述与荟萃分析
总体分析显示CHD患者HCC风险显著升高(合并OR 1.28;95%CI 1.05-1.57;I²=67.0%),前瞻性队列研究中关联更强(合并OR 2.77;95%CI 1.79-4.28;I²=0%),HIV感染患者中尤为显著(合并OR 7.13;95%CI 2.83-17.92;I²=0%)。
要点
- CHD患者HCC风险较HBV单感染显著升高,合并OR 1.28(95%CI 1.05-1.57)。
- 前瞻性队列研究中关联更强,合并OR 2.77(95%CI 1.79-4.28),无异质性。
- HIV合并感染者HCC风险显著增高,合并OR 7.13(95%CI 2.83-17.92)。
核心结论
- 慢性丁型肝炎患者发生肝细胞癌的风险显著高于慢性乙型肝炎单感染患者。
- 尽管需进一步研究排除抗病毒治疗等潜在偏倚,结果支持对慢性乙型肝炎患者加强丁型肝炎病毒筛查,并亟需新型有效抗病毒治疗。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Web of Science及研究参考文献和会议论文集。
- 采用随机效应模型合并数据,两名作者独立提取数据并使用Newcastle-Ottawa量表进行质量评价。
主要发现
- 总体分析显示CHD患者HCC风险显著升高,合并OR 1.28(95%CI 1.05-1.57;I²=67.0%),研究间存在显著异质性。
- 前瞻性队列研究中关联更强且无异质性,合并OR 2.77(95%CI 1.79-4.28;I²=0%)。
- HIV感染患者中关联尤为显著,合并OR 7.13(95%CI 2.83-17.92;I²=0%)。
临床怎么用
- 对慢性乙型肝炎患者应考虑筛查丁型肝炎病毒感染,以识别HCC高风险人群。
- 合并HIV感染的CHD患者HCC风险尤为突出,应加强监测。
- 需推动新型有效抗丁型肝炎病毒治疗的研发与应用。
局限性
- 研究间存在显著异质性(总体分析I²=67.0%)。
- 抗病毒治疗等潜在偏倚未能完全排除,需进一步研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic hepatitis D (CHD) is the most severe form of chronic viral hepatitis but its role in the development of hepatocellular carcinoma (HCC) remains debated. We conducted a systematic review and meta-analysis of epidemiological studies to examine whether CHD is associated with an increased risk of HCC. METHODS: We searched PubMed, Embase and Web of Science, as well as study references and conference proceedings. We considered cohort and case-control studies allowing the calculation of effect estimates for the association between CHD (exposure) and HCC (outcome) in comparison to chronic hepatitis B. Data extraction and quality evaluation (using the Newcastle-Ottawa scale) were performed independently by 2 authors. Data were pooled using random-effects models. RESULTS: Ninety-three studies (68 case-control studies including 22,862 patients and 25 cohort studies including 75,427 patients) were included. Twelve studies accounted for confounders, in either study design or analysis (10 of which were cohorts), and 11 cohorts were prospective. The overall analysis showed a significantly increased risk of HCC in patients with CHD, despite substantial study heterogeneity (pooled odds ratio 1.28; 95% CI 1.05-1.57; I2 = 67.0%). The association was particularly strong in the absence of heterogeneity for prospective cohort studies (pooled odds ratio 2.77; 95% CI 1.79-4.28; I2 = 0%), and studies with HIV-infected patients (pooled odds ratio 7.13; 95% CI 2.83-17.92; I2 = 0%). CONCLUSIONS: We found a significantly higher risk of HCC in patients with CHD. Although further studies are needed to definitively exclude a potential bias due to antiviral treatments, our findings highlight the rationale for improved screening of hepatitis D virus infection in patients with chronic hepatitis B, and the urgent need for novel and effective antiviral therapies. LAY SUMMARY: Hepatitis D virus (HDV) is a defective pathogen requiring hepatitis B virus (HBV) to complete its life cycle. Chronic hepatitis D is the most severe form of chronic viral hepatitis, increasing the risk of cirrhosis, liver decompensation and death compared to HBV monoinfection. However, the association between HDV infection and increased risk of hepatocellular carcinoma is debated. We conducted a systematic review and found that patients with HDV infection had a significantly higher risk of developing hepatocellular carcinoma than those with HBV monoinfection.
引用
- Alfaiate D, Clément S, Gomes D, et al. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol. 2020. PMID: 32151618. doi:10.1016/j.jhep.2020.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。